Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKōichi Goto, Pasi A. Jänne, Sang‐We Kim et al.|Journal of Clinical Oncology|2023Cited by 293
Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutationsSatoshi Inoue, Hiroyuki Mano, Yasushi Hirota et al.|Nature Communications|2019Cited by 137